전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved102 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleRocheApproved

rituximab (Rituxan)

US label: non-Hodgkin lymphoma, CLL, rheumatoid arthritis, GPA/MPA and pemphigus vulgaris; population-specific indicati… · CD20

#CD20#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1337Status Approved
ADCLimited DatastaleSeagenVedotin: A Retrospective Co…Approved

Bv (Brentuximab Vedotin, Brentuximab Vedotin (Bv))

Hodgkin Lymphoma (Category) · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Approved#Popular#antibody-drug-conjugate+4
Trials 195Status Active
CGTLimited DatastaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
ADCLimited DatastaleSeagenVedotin: A Retrospective Co…Phase 2

BV (Induction with Brentuximab vedotin, Induction with Brentuximab vedotin (BV))

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 119Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 65Status Active
CGTLimited DatastaleAbClonPhase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
ADCLimited DatastaleSeagenvedotin-containing regimen …Phase 2

BV (BrentuximabVedotin, BrentuximabVedotin (BV))

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 56Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleCRISPR Therapeutics AGPhase 1

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22 CAR (CD22 CAR)

B-ALL; B-cell Non Hodgkin Lymphoma · CD22

#CD22#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
ADCLimited DatastaleSeagenvedotin-containing regimen …Preclinical

SGN-35 (brentuximab vedotin, brentuximab vedotin (SGN-35))

Hodgkin Lymphoma · Hodgkin's Lymphoma

#HodgkinsLymphoma#ADC#Preclinical#Popular#antibody-drug-conjugate+4
Trials 52Status Active
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 1

JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) 2-dose schedule, lisocabtagene maraleucel)

Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 34Status Active
CGTLimited DatastaleShanghai Unicar-Therapy Bio-med…Phase 1

CD30+ CAR T-cells (CD30+ CAR T-cells)

Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 32Status Recruiting
AntibodyLimited DatastaleGrupo Español de Linfomas y Tra…Phase 2

Zevalin (Ibritumomab Tiuxetan, Ibritumomab Tiuxetan (Zevalin))

Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Non-HodgkinLymphoma+1
Trials 30Status Active
AntibodyLimited DatastaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#monoclonal-antibody#RecurrentDiffuseLargeB-CellLymph+2
Trials 30Status Recruiting
AntibodyLimited DatastaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#monoclonal-antibody#RecurrentAdultT-CellLeukemia+3
Trials 30Status Recruiting
AntibodyLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#LargeB-cellLymphoma+2
Trials 29Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#antibody-drug-conjugate#HodgkinLymphoma+2
Trials 25Status Recruiting
AntibodyCurated CorestaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+3
Trials 18Status Recruiting
CGTLimited DatastaleShanghai Mingju Biotechnology C…Phase 1

JWCAR029 (JWCAR029)

Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 14Status Active

1 / 6 pages

← PreviousNext →